```
=> file caplus
FILE 'CAPLUS' ENTERED AT 11:20:18 ON 14 JUN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 14 Jun 2007  VOL 146 ISS 25
FILE LAST UPDATED: 13 Jun 2007  (20070613/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d que
L2          101 SEA FILE=CAPLUS RABEPRAZOLE AND MAGNESIUM
L3           12 SEA FILE=CAPLUS L2 AND (AMORPHOUS OR CRYSTAL?)


=> d l3 1-12 ibib abs hit

L3   ANSWER 1 OF 12  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2007:435918  CAPLUS
DOCUMENT NUMBER:         146:428764
TITLE:                   Salts of proton pump inhibitors and process for
                         preparing same
INVENTOR(S):             Hackett, John Allen
PATENT ASSIGNEE(S):      Jon Pty Limited, Australia
SOURCE:                  PCT Int. Appl., 37pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2007041790         A1    20070419    WO 2006-AU1499          20061011
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
             KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
             MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
             RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                   AU 2005-905699      A  20051014
AB   Disclosed herein is a process for preparing magnesium and
```

magnesium hydroxy salts of proton pump inhibitors (PPI) such as omeprazole, hydroxy omeprazole, s-omeprazole (esomeprazole), r-omeprazole, pantoprazole, lanzoprazole, leminoprazole, rabeprazole, tenatoprazole, mixts. thereof or resp. isomers thereof. The process can be used to prepare magnesium salts of PPIs. In particular the process can also be used to prepare the magnesium hydroxy salts of PPIs which have the formula: (PPI-)x.Mg2+(OH-)2-x.(H2O)z wherein PPI is a proton pump inhibitor, x is 0.0001 to 1.9999, and z is 0 to 10, preferably 0 to 5. Compns. of the salts of the PPIs disclosed herein including pharmaceutical compns. are also disclosed. The magnesium and magnesium hydroxy salts of proton pump inhibitors disclosed herein can be used in the treatment of gastrointestinal disorders such as Ulcus ventriculi, Ulcus duodeni, gastritis, gastric ulcer, duodenal ulcer, irritable bowel owing to an increased production of acid or as a result of medicaments, GERD, Crohn's disease or IBD. Magnesium hydroxy salt of omeprazole was prepared by the reaction of magnesium hydroxide with omeprazole. A tablet contained magnesium hydroxy salt of omeprazole containing 10% imeprazole 200, anhydrous lactose 141, croscarmellose sodium 6.0, and magnesium stearate 3.0 mg.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB Disclosed herein is a process for preparing magnesium and magnesium hydroxy salts of proton pump inhibitors (PPI) such as omeprazole, hydroxy omeprazole, s-omeprazole (esomeprazole), r-omeprazole, pantoprazole, lanzoprazole, leminoprazole, rabeprazole, tenatoprazole, mixts. thereof or resp. isomers thereof. The process can be used to prepare magnesium salts of PPIs. In particular the process can also be used to prepare the magnesium hydroxy salts of PPIs which have the formula: (PPI-)x.Mg2+(OH-)2-x.(H2O)z wherein PPI is a proton pump inhibitor, x is 0.0001 to 1.9999, and z is 0 to 10, preferably 0 to 5. Compns. of the salts of the PPIs disclosed herein including pharmaceutical compns. are also disclosed. The magnesium and magnesium hydroxy salts of proton pump inhibitors disclosed herein can be used in the treatment of gastrointestinal disorders such as Ulcus ventriculi, Ulcus duodeni, gastritis, gastric ulcer, duodenal ulcer, irritable bowel owing to an increased production of acid or as a result of medicaments, GERD, Crohn's disease or IBD. Magnesium hydroxy salt of omeprazole was prepared by the reaction of magnesium hydroxide with omeprazole. A tablet contained magnesium hydroxy salt of omeprazole containing 10% imeprazole 200, anhydrous lactose 141, croscarmellose sodium 6.0, and magnesium stearate 3.0 mg.

ST proton pump inhibitor salt prepn magnesium omeperazole

IT Crystallinity
Digestive tract, disease
(salts of proton pump inhibitors and process for preparing same)

IT 95382-33-5P, Magnesium omeprazole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(salts of proton pump inhibitors and process for preparing same)

IT 1309-42-8, Magnesium hydroxide
RL: RCT (Reactant); RACT (Reactant or reagent)
(salts of proton pump inhibitors and process for preparing same)

IT 92340-57-3, Hydroxy omeprazole 102625-70-7, Pantoprazole 103577-45-3 104340-86-5, Leminoprazole 113712-98-4, Tenatoprazole 117976-89-3, Rabeprazole 119141-88-7, s-Omeprazole 138530-94-6, r-Lansoprazole 138530-95-7, s-Lansoprazole 142678-35-1, s-Pantoprazole 142706-18-1, r-Pantoprazole 177795-59-4, s-Rabeprazole 177795-60-7, r-Rabeprazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(salts of proton pump inhibitors and process for preparing same)

L3 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:982400 CAPLUS
DOCUMENT NUMBER: 145:342507
TITLE: Stable tablet dosage forms of proton pump inhibitors
INVENTOR(S): Namburi, Ranga R.; Karri, Rama Prasad; Tallapragada, Ravi Srikanth; Palkhiwala, Burgise F.
PATENT ASSIGNEE(S): Qpharma, LLC, USA
SOURCE: U.S. Pat. Appl. Publ., 12pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006210637	A1	20060921	US 2005-82610	20050317
WO 2006101794	A2	20060928	WO 2006-US8855	20060314
WO 2006101794	A3	20070104		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-82610 A 20050317
AB This invention relates to a method of making oral formulations of practically water insol., or very slightly water soluble proton pump inhibitors, the oral dosage forms so made, and methods of use thereof. The oral dosage form has a core tablet of compressed particles composed of powder particles of a pharmaceutically acceptable material, having coated thereon admixt. of an amorphous, salt form of a benzimidazole proton pump inhibitor produced in-situ; and a pharmaceutically acceptable, water-soluble, hydrophilic polymer having a surfactant functionality. The coated core tablet has a pharmaceutically acceptable sub-coating on the core tablet; and a pharmaceutically acceptable enteric coating on the sub-coating. The coated tablet may provide enhanced absorption when administered orally. A core tablet containing omeprazole 20.0 mg was coated with Opadry 03K19299 5.517, and disodium hydrogen phosphate 0.184 to obtain a delayed-release tablet.
AB This invention relates to a method of making oral formulations of practically water insol., or very slightly water soluble proton pump inhibitors, the oral dosage forms so made, and methods of use thereof. The oral dosage form has a core tablet of compressed particles composed of powder particles of a pharmaceutically acceptable material, having coated thereon admixt. of an amorphous, salt form of a benzimidazole proton pump inhibitor produced in-situ; and a pharmaceutically acceptable, water-soluble, hydrophilic polymer having a surfactant functionality. The coated core tablet has a pharmaceutically acceptable sub-coating on the core tablet; and a pharmaceutically acceptable enteric coating on the sub-coating. The coated tablet may provide enhanced absorption when administered orally. A core tablet containing omeprazole 20.0 mg was coated with Opadry 03K19299 5.517, and disodium hydrogen phosphate 0.184 to obtain a delayed-release tablet.
IT 471-34-1, Precipitated calcium carbonate, biological studies 546-93-0, Magnesium carbonate 1305-62-0, Calcium hydroxide, biological studies 1309-42-8, Magnesium hydroxide 1309-48-4, Magnesium oxide, biological studies 1310-58-3, Potassium

hydroxide, biological studies 1310-73-2, Sodium hydroxide, biological studies 1336-21-6, Ammonium hydroxide 1343-88-0, Magnesium silicate 7558-79-4, Disodium hydrogen phosphate 9004-65-3, Hydroxypropyl methyl cellulose. 11137-98-7, Magnesium aluminate 12511-31-8 39366-43-3, Aluminum magnesium hydroxide 57237-97-5, Timoprazole 73590-58-6, Omeprazole 99499-40-8, Disuprazole 102625-70-7, Pantoprazole 103577-45-3, Lansoprazole 104340-86-5, Leminoprazole 113712-98-4, Tenatoprazole 117976-89-3, Rabeprazole 119141-88-7, Esomeprazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable tablet dosage forms of proton pump inhibitors)

L3 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:952866 CAPLUS
DOCUMENT NUMBER: 145:321808
TITLE: Pharmaceutical formulations for inhibiting acid secretion
INVENTOR(S): Hall, Warren; Olmstead, Kay; Weston, Laura
PATENT ASSIGNEE(S): Santarus, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 56pp., Cont.-in-part of U.S. Ser. No. 893,203.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2006204585	A1	20060914	US 2006-338608		20060124
US 2005037070	A1	20050217	US 2004-893203		20040716
PRIORITY APPLN. INFO.:			US 2003-488321P	P	20030718
			US 2004-893203	A2	20040716

AB In one general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a material that enhances the shelf-life of the pharmaceutical composition and one or more antacids are described. In another general aspect of the present invention, pharmaceutical formulations comprising both a proton pump inhibitor microencapsulated or dry coated with a taste-masking material and one or more antacid are described. Thus, dry granules contained omeprazole 10, sodium bicarbonate 85, Klucel 5, and Mg stearate 0.3 mg.

IT Antacids
Binders
Dissolution
Drug bioavailability
Flavoring materials
Human
Mint
Particle size distribution
Pharmacokinetics
Polymorphism (crystal)
Prunus persica
Sweetening agents
(pharmaceutical formulations for inhibiting acid secretion)

IT 117976-89-3, Rabeprazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Habeprazole; pharmaceutical formulations for inhibiting acid secretion)

IT 57-50-1, Sucrose, biological studies 87-99-0, Xylitol 144-55-8, Sodium bicarbonate, biological studies 298-14-6, Potassium bicarbonate 471-34-1, Calcium carbonate, biological studies 497-19-8, Sodium carbonate, biological studies 546-93-0, Magnesium carbonate

1309-42-8, Magnesium hydroxide 1309-48-4, Magnesium oxide, biological studies 1490-04-6, Menthol 9004-64-2, Hydroxypropyl cellulose 21645-51-2, Aluminum hydroxide, biological studies 22839-47-0, Aspartame 56038-13-2, Sucralose 92340-57-3, Hydroxyomeprazole 95382-33-5, Omeprazole magnesium 102625-70-7, Pantoprazole 103577-45-3, Lansoprazole 104340-86-5, Leminoprazole 113712-98-4, Tenatoprazole 117976-90-6, Pariprazole 119141-88-7, Esomeprazole 138786-67-1, Pantoprazole sodium 161973-10-0, Perprazole 350507-35-6, Dontoprazole 832103-67-0, Ransoprazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulations for inhibiting acid secretion)

L3 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:632746 CAPLUS
DOCUMENT NUMBER: 145:90024
TITLE: Stable oral benzimidazole compositions
INVENTOR(S): Gandhi, Rajesh; Issa, Chayapathy; Nagaprasad, Vishnubhotla
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006067599	A2	20060629	WO 2005-IB3858	20051222
WO 2006067599	A3	20060824		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: IN 2004-DE2551 A 20041223

AB The present invention relates to stable oral compns. of one or more benzimidazole compds. and processes for their preparation Also provided are methods for treating various gastrointestinal disorders. Thus, a benzimidazole core contained amorphous esomeprazole magnesium 44.5, HPC 20.0, and Kollidon CLM 30.0 mg/capsule, and water qs.

AB The present invention relates to stable oral compns. of one or more benzimidazole compds. and processes for their preparation Also provided are methods for treating various gastrointestinal disorders. Thus, a benzimidazole core contained amorphous esomeprazole magnesium 44.5, HPC 20.0, and Kollidon CLM 30.0 mg/capsule, and water qs.

IT 50-70-4, Sorbitol, biological studies 50-99-7, Glucose, biological studies 51-17-2D, Benzimidazole, derivs. 57-50-1, Sucrose, biological studies 63-42-3, Lactose 69-65-8, Mannitol 151-21-3, Sodium lauryl sulfate, biological studies 557-04-0, Magnesium stearate 4070-80-8, Sodium stearyl fumarate 9003-39-8 9004-32-4, Sodium carboxymethyl cellulose 9004-34-6D, Cellulose, derivs. 9004-64-2, Hydroxypropyl cellulose 9004-65-3 9005-25-8, Starch, biological

studies 9005-38-3, Sodium alginate 9005-65-6 9063-38-1 14807-96-6, Talc, biological studies 25086-89-9 25212-88-8, Eudragit L30D 55 73590-58-6, Omeprazole 74811-65-7, Croscarmellose sodium 95382-33-5, Omeprazole magnesium 102625-70-7, Pantoprazole 103577-45-3, Lansoprazole 104340-86-5, Leminoprazole 117976-89-3, Rabeprazole 117976-90-6, Pariprazole 161973-10-0, Esomeprazole magnesium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable oral benzimidazole compns.)

L3 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:630739 CAPLUS
DOCUMENT NUMBER: 145:90005
TITLE: Compositions comprising amorphous benzimidazole compounds
INVENTOR(S): Bhushan, Indu; Vermani, Kavita; Kodipyaka, Ravinder; Mehta, Pavak; Mohan, Mailatur Sivaraman
PATENT ASSIGNEE(S): Dr. Reddy's Laboratories Ltd., India; Dr. Reddy's Laboratories, Inc.
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006069159	A2	20060629	WO 2005-US46393	20051220
WO 2006069159	A3	20061221		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: IN 2004-CH1401 A 20041220
AB The present invention relates to the processes for the preparation of pharmaceutical compns. comprising the amorphous form of substituted benzimidazoles or their pharmaceutically acceptable salts, solvates, enantiomers or mixts. thereof, methods of use and treatment of different disease conditions using these compns. For example, esomeprazole magnesium (amorphous) 40 mg was dissolved in methanol, then mannitol 37 mg and meglumine 3 mg were dispersed in the solution The resulting dispersion was spray dried.
TI Compositions comprising amorphous benzimidazole compounds
AB The present invention relates to the processes for the preparation of pharmaceutical compns. comprising the amorphous form of substituted benzimidazoles or their pharmaceutically acceptable salts, solvates, enantiomers or mixts. thereof, methods of use and treatment of different disease conditions using these compns. For example, esomeprazole magnesium (amorphous) 40 mg was dissolved in methanol, then mannitol 37 mg and meglumine 3 mg were dispersed in the solution The resulting dispersion was spray dried.
IT Drying
(agitated; compns. comprising amorphous benzimidazole compds.)

IT Amides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carboxymethyl derivs.; compns. comprising amorphous benzimidazole compds.)
IT Crystal morphology
(compns. comprising amorphous benzimidazole compds.)
IT Alditols
Carbohydrates, biological studies
Glass, biological studies
Plastics, biological studies
Polyoxyalkylenes, biological studies
Polysaccharides, biological studies
Zeins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising amorphous benzimidazole compds.)
IT Drying
(fluidized-bed; compns. comprising amorphous benzimidazole compds.)
IT Drug delivery systems
(pellets, controlled-release; compns. comprising amorphous benzimidazole compds.)
IT Drug delivery systems
(pellets, enteric-coated; compns. comprising amorphous benzimidazole compds.)
IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyhydric; compns. comprising amorphous benzimidazole compds.)
IT Drying
(spray; compns. comprising amorphous benzimidazole compds.)
IT Drying
(vacuum; compns. comprising amorphous benzimidazole compds.)
IT 67-56-1, Methanol, uses 67-63-0, Isopropyl alcohol, uses
RL: NUU (Other use, unclassified); USES (Uses)
(compns. comprising amorphous benzimidazole compds.)
IT 51-17-2, Benzimidazole 69-65-8, Mannitol 77-93-0, Triethyl citrate
88-12-0D, polymer 557-04-0, Magnesium stearate 1309-48-4,
Magnesium oxide, biological studies 6284-40-8, Meglumine
9003-39-8, Povidone K30 9004-34-6, CELPHERE CP 203, biological studies
9004-34-6D, Cellulose, derivative 9004-65-3, Hydroxypropyl methylcellulose
9005-65-6, Polysorbate 80 13463-67-7, Titanium oxide, biological studies
14807-96-6, Talc, biological studies 25086-15-1, EUDRAGIT L 100
25086-89-9, Plasdone S 630 25322-68-3, Polyethylene glycol 31566-31-1,
Glyceryl monostearate 57237-97-5, Timoprazole 73590-58-6, Omeprazole
95382-33-5, Omeprazole magnesium 99499-40-8, Disuprazole
102625-70-7, Pantoprazole 103577-45-3, Lansoprazole 104340-86-5,
Leminoprazole 113712-98-4, Tenatoprazole 117976-89-3,
Rabeprazole 117976-90-6, Pariprazole 119141-88-7, Esomeprazole
161973-10-0, Esomeprazole magnesium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising amorphous benzimidazole compds.)

L3 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:11840 CAPLUS
DOCUMENT NUMBER: 144:94384
TITLE: Stable pharmaceutical formulations of benzimidazole compounds
INVENTOR(S): Teva Pharmaceuticals USA, Inc.; Shterman, Nava; Di Capua, Simona; Moshe, Benny; Itah, Esther
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

10/541,140

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006002077	A2	20060105	WO 2005-US21085	20050615
WO 2006002077	A3	20061116		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005257977	A1	20060105	AU 2005-257977	20050615
CA 2570796	A1	20060105	CA 2005-2570796	20050615
US 2006051421	A1	20060309	US 2005-153954	20050615
EP 1755566	A2	20070228	EP 2005-760650	20050615
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				

PRIORITY APPLN. INFO.:

US 2004-580273P	P	20040615
US 2004-588233P	P	20040714
US 2004-591784P	P	20040727
US 2004-580273	A	20040615
US 2004-588233	A	20040714
US 2004-591784	A	20040727
WO 2005-US21085	W	20050615

AB Provided are stable pharmaceutical formulations of benzimidazole compds., particularly esomeprazole magnesium, and processes for their preparation
AB Provided are stable pharmaceutical formulations of benzimidazole compds., particularly esomeprazole magnesium, and processes for their preparation
ST esomeprazole magnesium prepn formulation
IT Antacids
Binders
Crystal morphology
Drug delivery systems
Particle size distribution
Stabilizing agents
(stable pharmaceutical formulations of benzimidazole compds.)
IT 50-99-7, Dextrose, biological studies 57-50-1, Sucrose, biological studies 77-86-1, Tris(hydroxymethyl)aminomethane 79-41-4D, Methacrylic acid, polymers 471-34-1, Calcium carbonate, biological studies 497-19-8, Sodium carbonate, biological studies 546-93-0, Magnesium carbonate 1309-48-4, Magnesium oxide, biological studies 9000-11-7, Carboxymethyl cellulose 9002-89-5, Polyvinyl alcohol 9003-39-8, Polyvinyl pyrrolidone 9004-57-3, Ethylcellulose 9004-64-2, Hydroxypropylcellulose 9004-65-3, Hydroxypropylmethylcellulose 9004-67-5, Methylcellulose 9005-25-8, Starch, biological studies 9050-31-1, Hydroxypropyl methyl cellulose phthalate 70535-77-2, Hydroxypropyl methylcellulose acetate succinate 71138-97-1, Hydroxypropyl methylcellulose acetate succinate
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable pharmaceutical formulations of benzimidazole compds.)

IT 73590-58-6, Omeprazole 102625-70-7, Pantoprazole 103577-45-3, Lansoprazole 117976-89-3, Rabeprazole 119141-88-7, Esomeprazole 161973-10-0, Esomeprazole magnesium
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(stable pharmaceutical formulations of benzimidazole compds.)

L3 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:979640 CAPLUS
DOCUMENT NUMBER: 143:286424
TITLE: Neutralization process for the preparation of the magnesium salt of omeprazole
INVENTOR(S): Toker, Bedri; Merey, Sebnur
PATENT ASSIGNEE(S): Milen Merkez Ilac Endustrisi A. S., Turk.
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082888	A1	20050909	WO 2004-TR14	20040301

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: WO 2004-TR14 20040301

AB A process for the preparation of the magnesium salt of omeprazole is described which comprises the reaction of omeprazole with magnesium hydroxide that is a weak inorg. base as magnesium source. Using this method, the difficulties caused by magnesium hydroxide that is formed during omeprazole magnesium salt preparation can be eliminated and omeprazole magnesium can be obtained in high yield and purity.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Neutralization process for the preparation of the magnesium salt of omeprazole

AB A process for the preparation of the magnesium salt of omeprazole is described which comprises the reaction of omeprazole with magnesium hydroxide that is a weak inorg. base as magnesium source. Using this method, the difficulties caused by magnesium hydroxide that is formed during omeprazole magnesium salt preparation can be eliminated and omeprazole magnesium can be obtained in high yield and purity.

ST omeprazole magnesium manuf

IT Crystallization
Filtration
Washing
(in a neutralization process for the preparation of the magnesium salt of omeprazole)

IT Neutralization
(of omeprazole with magnesium hydroxide in the preparation of the

magnesium salt of omeprazole)
IT Ethers, uses
RL: NUU (Other use, unclassified); USES (Uses)
(solvents; in a neutralization process for the preparation of the magnesium salt of omeprazole)
IT Drug delivery systems
(tablets; preparation of the magnesium salt of omeprazole for use in)
IT Distillation
(vacuum; in a neutralization process for the preparation of the magnesium salt of omeprazole)
IT 1309-42-8, Magnesium hydroxide 73590-58-6, Omeprazole
RL: RCT (Reactant); RACT (Reactant or reagent)
(in a neutralization process for the preparation of the magnesium salt of omeprazole)
IT 95382-33-5P, Omeprazole magnesium
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(neutralization process for the preparation of the magnesium salt of omeprazole)
IT 161796-85-6P, Esomeprazole calcium 161973-10-0P, Esomeprazole magnesium 199387-73-0P, Magnesium pantoprazole 226904-11-6P, Lansoprazole calcium 226904-51-4P, Pantoprazole calcium 226904-99-0P, Rabeprazole calcium 718599-74-7P 728915-40-0P, Leminoprazole magnesium 864383-40-4P, Leminoprazole calcium
RL: PNU (Preparation, unclassified); PREP (Preparation)
(preparation of)
IT 64-17-5, Ethanol, uses 67-56-1, Methanol, uses 109-99-9, Thf, uses 141-78-6, Ethyl acetate, uses 7732-18-5, Water, uses
RL: NUU (Other use, unclassified); USES (Uses)
(solvent; in a neutralization process for the preparation of the magnesium salt of omeprazole)

L3 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:638706 CAPLUS
DOCUMENT NUMBER: 143:159548
TITLE: Donepezil formulations
INVENTOR(S): Boehm, Garth; Dundon, Josephine
PATENT ASSIGNEE(S): Alpharma, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065645	A2	20050721	WO 2004-US42999	20041223
WO 2005065645	A3	20051027		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2552221	A1	20050721	CA 2004-2552221	20041223

US 2005232990	A1	20051020	US 2004-22346		20041223
EP 1776089	A2	20070425	EP 2004-815115		20041223
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
PRIORITY APPLN. INFO.:			US 2003-533496P	P	20031231
			WO 2004-US42999	W	20041223

AB Donepezil formulations, including amorphous donepezil or pharmaceutically acceptable salts thereof; sustained-release formulations; and donepezil sprinkle formulations are disclosed.

AB Donepezil formulations, including amorphous donepezil or pharmaceutically acceptable salts thereof; sustained-release formulations; and donepezil sprinkle formulations are disclosed.

IT 144-55-8, Sodium bicarbonate, biological studies 471-34-1, Calcium carbonate, biological studies 1309-42-8, Magnesium hydroxide 14455-29-9, Aluminum carbonate 21645-51-2, Aluminum hydroxide, biological studies 51481-61-9, Cimetidine 66357-35-5, Ranitidine 73590-58-6, Omeprazole 76824-35-6, Famotidine 76963-41-2, Nizatidine 102625-70-7, Pantoprazole 103577-45-3, Lansoprazole 117976-89-3, Rabeprazole 119141-88-7, Esomeprazole 161973-10-0, Esomeprazole magnesium
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(donepezil formulations)

L3 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:99328 CAPLUS
DOCUMENT NUMBER: 142:183479
TITLE: Immediate-release formulation of acid-labile drugs
INVENTOR(S): Phillips, Jeffrey O.; Widder, Ken J.
PATENT ASSIGNEE(S): The Curators of the University of Missouri, USA; Santarus, Inc.
SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005009381	A2	20050203	WO 2004-US23558		20040722
WO 2005009381	A3	20050616			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004258984	A1	20050203	AU 2004-258984		20040722
CA 2533588	A1	20050203	CA 2004-2533588		20040722
US 2005112193	A1	20050526	US 2004-896682		20040722
EP 1660043	A2	20060531	EP 2004-778879		20040722
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
JP 2006528198	T	20061214	JP 2006-521232		20040722
PRIORITY APPLN. INFO.:			US 2003-489363P	P	20030723
			WO 2004-US23558	W	20040722

AB The present invention provides, inter alia, compns. comprising a pH buffering agent and a controlled-release component containing an acid-labile

pharmaceutical. Methods of using such compns. are also provided. Microgranules of omeprazole were coated with Eudragit L30D-55.

IT Antibacterial agents
Antioxidants
Binders
Buffers
Digestive tract, disease
Drug bioavailability
Dyes
Dyspepsia
Esophagus, disease
Fillers
Flavoring materials
Fungicides
Lubricants
Polymorphism (crystal)
Preservatives
Solubilizers
Stabilizing agents
Sweetening agents
Wetting agents
(immediate-release formulation of acid-labile drugs)

IT 62-54-4, Calcium acetate 68-04-2, Sodium citrate 72-17-3, Sodium lactate 77-86-1, Trishydroxymethylaminomethane 77-92-9, Citric acid, biological studies 77-93-0, Triethyl citrate 79-41-4D, Methacrylic acid, polymers 84-66-2, Diethyl phthalate 102-76-1, Triacetin 112-92-5, Stearyl alcohol 127-08-2, Potassium acetate 127-09-3, Sodium acetate 140-99-8, Calcium succinate 142-72-3, Magnesium acetate 144-55-8, NaHCO3, biological studies 150-90-3, Disodium succinate 151-21-3, Sodium lauryl sulfate, biological studies 298-14-6, Potassium bicarbonate 471-34-1, Calcium carbonate, biological studies 497-19-8, Sodium carbonate, biological studies 533-96-0, Sodium sesquicarbonate 546-93-0, Magnesium carbonate 549-14-4, Magnesium phthalate 556-32-1, Magnesium succinate 584-08-7, Potassium carbonate 814-80-2, Calcium lactate 866-84-2, Potassium citrate 1305-62-0, Calcium hydroxide, biological studies 1309-42-8, Magnesium hydroxide 1309-48-4, MgO, biological studies 1310-73-2, Sodium hydroxide, biological studies 1330-43-4, Sodium borate 1332-77-0, Potassium borate 1343-88-0, Magnesium silicate 2090-64-4, Magnesium bicarbonate 3164-34-9, Calcium tartrate 3983-19-5, Calcium bicarbonate 5793-85-1, Calcium phthalate 7320-34-5, Potassium pyrophosphate 7558-79-4, Dibasic sodium phosphate 7558-80-7, Sodium dihydrogen phosphate 7601-54-9, Trisodium phosphate 7632-05-5, Sodium phosphate 7693-13-2, Calcium citrate 7722-84-1, Hydrogen peroxide, biological studies 7722-88-5, Sodium pyrophosphate 7758-11-4, Dipotassium hydrogen phosphate 7758-29-4, Sodium tripolyphosphate 7778-53-2, Tripotassium phosphate 7779-25-1, Magnesium citrate 7790-53-6, Potassium metaphosphate 9002-89-5, Poly(vinyl alcohol) 9003-39-8, Polyvinylpyrrolidone 9004-32-4 9004-35-7, Cellulose acetate 9004-36-8, Cellulose acetate butyrate 9004-38-0, Cellulose acetate phthalate 9004-57-3, Ethyl cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl methyl cellulose 9005-65-6, Polysorbate 80 9010-88-2, Eudragit NE30D 9050-31-1, Hydroxypropyl methyl cellulose phthalate 10043-52-4, Calcium chloride, biological studies 10043-83-1, Magnesium phosphate 10103-46-5, Calcium phosphate 10197-71-4, Sodium phthalate 11137-98-7, Magnesium aluminate 12304-65-3, Hydrotalcite 12511-31-8 12619-64-6, Magnesium borate 13840-55-6, Calcium borate 14047-56-4, Sodium succinate 14475-11-7, Sodium tartrate 16068-46-5, Potassium phosphate 18917-93-6, Magnesium lactate 20752-56-1, Magnesium tartrate 21645-51-2, Aluminum hydroxide (Al(OH)3), biological studies 22445-04-1, Potassium succinate 25086-15-1, Eudragit L100 25212-88-8,

Kollicoat MAE30DP 25212-88-8, Eudragit L30D-55 25322-68-3, Macrogol 6000 26936-24-3, Eudragit FS30D 27214-00-2, Calcium glycerophosphate 29801-94-3, Potassium phthalate 31566-31-1, Glyceryl monostearate 36653-82-4, Cetyl alcohol 39366-43-3, Aluminum Magnesium hydroxide 40968-90-9, Potassium tartrate 52907-01-4, Cellulose acetate trimellitate 53237-50-6, Poly(vinyl acetate) phthalate 71138-97-1, Hydroxypropyl methyl cellulose acetate succinate 73590-58-6, Omeprazole 102625-70-7, Pantoprazole 103577-45-3, Lansoprazole 104340-86-5, Leminoprazole 113712-98-4, Tenatoprazole 117976-89-3, Rabeprazole 117976-90-6, Pariprazole 119141-88-7, Esomeprazole 835648-57-2, Polyquid PA 30
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(immediate-release formulation of acid-labile drugs)

L3 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:354792 CAPLUS
DOCUMENT NUMBER: 140:327137
TITLE: Stable solid preparations containing amorphous benzimidazoles and salts
INVENTOR(S): Nonomura, Muneo; Ito, Hiroki; Hashimoto, Hideo; Urai, Tadashi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035052	A1	20040429	WO 2003-JP13152	20031015
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2502219	A1	20040429	CA 2003-2502219	20031015
AU 2003273000	A1	20040504	AU 2003-273000	20031015
JP 2004155773	A	20040603	JP 2003-354904	20031015
EP 1552833	A1	20050713	EP 2003-754113	20031015
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006057195	A1	20060316	US 2005-530785	20050408
PRIORITY APPLN. INFO.:			JP 2002-301893 A	20021016
			WO 2003-JP13152 W	20031015

OTHER SOURCE(S): MARPAT 140:327137
AB It is intended to provide a process for producing unstable amorphous benzimidazole compds. having a proton pump inhibitor function, and stable solid prepns. for medicinal use containing these compds. which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorg. salt, forming an intermediate coating layer on the layer containing the active ingredient and further forming an enteric coating layer or a release-controlling coating layer. For example, granules were formulated containing amorphous (R)-lansoprazole, MgCO3, and excipients, treated with an enteric-soluble coating composition containing methacrylate copolymer, then filled into capsules.

REFERENCE COUNT: 164 THERE ARE 164 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Stable solid preparations containing amorphous benzimidazoles and salts

AB It is intended to provide a process for producing unstable amorphous benzimidazole compds. having a proton pump inhibitor function, and stable solid prepns. for medicinal use containing these compds. which are produced by blending such an amorphous benzimidazole compound with a nontoxic base such as a basic inorg. salt, forming an intermediate coating layer on the layer containing the active ingredient and further forming an enteric coating layer or a release-controlling coating layer. For example, granules were formulated containing amorphous (R)-lansoprazole, MgCO3, and excipients, treated with an enteric-soluble coating composition containing methacrylate copolymer, then filled into capsules.

ST amorphous benzimidazole proton pump inhibitor salt granule stability; lansoprazole magnesium carbonate granule enteric coating capsule

IT Drug delivery systems
(capsules; stable solid prepns. containing amorphous benzimidazole proton pump inhibitors and salts)

IT Transport proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(proton pump, inhibitors; stable solid prepns. containing amorphous benzimidazole proton pump inhibitors and salts)

IT Drug delivery systems
(solids, enteric-coated; stable solid prepns. containing amorphous benzimidazole proton pump inhibitors and salts)

IT 313640-86-7
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable solid prepns. containing amorphous benzimidazole proton pump inhibitors and salts)

IT 144-55-8, Sodium hydrogen carbonate, biological studies 471-34-1, Calcium carbonate, biological studies 497-19-8, Sodium carbonate, biological studies 546-93-0, Magnesium carbonate 1309-42-8, Magnesium hydroxide 1309-48-4, Magnesia, biological studies 1343-88-0, Magnesium silicate 7647-14-5, Sodium chloride, biological studies 12304-65-3, Hydrotalcite 21645-51-2, Aluminum hydroxide, biological studies 119141-88-7, S-Omeprazole 119141-89-8 138530-94-6 138530-95-7, S-Lansoprazole 142678-35-1, S-Pantoprazole 142706-18-1 177795-59-4, S-Rabeprazole 177795-60-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable solid prepns. containing amorphous benzimidazole proton pump inhibitors and salts)

L3 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:610242 CAPLUS
DOCUMENT NUMBER: 139:154933
TITLE: Transmucosal delivery of proton pump inhibitors
INVENTOR(S): Widder, Ken; Hall, Warren; Olmstead, Kay
PATENT ASSIGNEE(S): Santarus, Inc., USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003063840	A2	20030807	WO 2003-US2659	20030127

WO 2003063840 A3 20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2472103 A1 20030807 CA 2003-2472103 20030127
US 2004006111 A1 20040108 US 2003-353143 20030127
EP 1469839 A2 20041027 EP 2003-705972 20030127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2005521662 T 20050721 JP 2003-563534 20030127
PRIORITY APPLN. INFO.: US 2002-351909P P 20020125
US 2002-374761P P 20020422
WO 2003-US2659 W 20030127

AB The present invention relates to pharmaceutical compns. and methods for transmucosal delivery of proton pump inhibitors. In one embodiment, the pharmaceutical composition of the present invention comprises a core which comprises an antacid, and an outer layer surrounding the core. The outer layer contains a therapeutically effective amount of a proton pump inhibitor. In another embodiment, the pharmaceutical composition of the present invention comprises an outer layer which comprising a unidirectional film, and an inner layer which contains a therapeutically effective amount of a proton pump inhibitor. In yet another embodiment, the pharmaceutical composition of the present invention is a unidirectional tablet for delivery of a proton pump inhibitor across the oral mucosa. In this embodiment, the pharmaceutical composition contains an outer layer which contains a pharmaceutically acceptable water impermeable layer, and an inner layer which contains a therapeutically effective amount of a proton pump inhibitor. A tablet composition contained in the outer layer; Klucel EXP 10, dicalcium phosphate 10, MgCO3-90S 20, FD&C Lake Red Number 0.1, and Compitol-888 1 mg/tablet; the inner layer comprised omeprazole 20, MgCO3-90S 20, Klucel EXP 10, and Mg stearate 0.6 mg/tablet.

IT Antacids
Beeswax
Enantiomers
Flavoring materials
Polymorphism (crystal)
Solubilizers
(transmucosal delivery of proton pump inhibitors)

IT 87-99-0, Xylitab 100 144-55-8, Carbonic acid monosodium salt, biological studies 298-14-6 471-34-1, Calcium carbonate, biological studies 546-93-0, Magnesium carbonate 584-08-7 9002-88-4, Polyethylene 9004-34-6D, Cellulose, alkyl ethers 9004-64-2, Hydroxypropyl cellulose 12619-70-4, Cyclodextrin 18641-57-1 25038-59-9, Mylar, biological studies 73590-58-6, Omeprazole 74811-65-7, Croscarmellose sodium 77538-19-3, Glyceryl behenate 92340-57-3, HydroxyOmeprazole 102625-70-7, Pantoprazole 103577-45-3, Lansoprazole 104340-86-5, Leminoprazole 117976-89-3, Rabeprazole 117976-90-6, Pariprazole 119141-88-7, Esomeprazole 161973-10-0, Perprazole 350507-35-6, Dontoprazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transmucosal delivery of proton pump inhibitors)

L3 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:338762 CAPLUS
DOCUMENT NUMBER: 134:362292
TITLE: Methods of determining individual hypersensitivity to

a pharmaceutical agent from gene expression profile

INVENTOR(S): Farr, Spencer
PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA

SOURCE: PCT Int. Appl., 222 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105
US 2000-196571P P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also disclosed.

IT Crystallins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(ζ- crystallins; methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile)

IT 3778-73-2, Iphosphamide 3930-20-9, Sotalol 4205-90-7, Clonidine 4419-39-0, Beclomethasone 4499-40-5, Oxtriphylline, biological studies 4618-18-2, Lactulose 4697-36-3, Carbenicillin 4759-48-2, Isotretinoin 5051-62-7, Guanabenz 5543-57-7, (s)-Warfarin 5633-20-5, Oxybutynin 5786-21-0, Clozapine 6190-39-2, Dihydroergotamine mesylate 6493-05-6, Pentoxifylline 6621-47-2, Perhexiline 7020-55-5, Clidinium 7235-40-7, Beta carotene 7261-97-4, Dantrolene 7416-34-4, Molindone 7439-93-2, Lithium, biological studies 7447-40-7, Potassium chloride, biological studies 7481-89-2, Zalcitabine 7487-88-9, Magnesium sulfate, biological studies 7648-98-8, Ambenonium 7681-11-0, Potassium iodide, biological studies 7681-93-8, Natamycin 7683-59-2, Isoproterenol 8029-99-0, Paregoric 8049-47-6, Pancreatin 8050-81-5, Simethicone 8063-07-8, Kanamycin 8067-24-1, Ergoloid mesylates

9001-27-8, BLood-coagulation factor VIII 9001-75-6, Pepsin 9004-10-8, Insulin, biological studies 9004-67-5, Methyl cellulose 9005-49-6, Enoxaparin, biological studies 9007-92-5, Glucagon, biological studies 9039-53-6, Urokinase 9046-56-4, Ancrod 10118-90-8, Minocycline 10238-21-8, Glyburide 10262-69-8, Maprotiline 10540-29-1, Tamoxifen 11041-12-6, Cholestyramine 11056-06-7, Bleomycin 11111-12-9, Cephalosporin 12174-11-7, Attapulgite 12244-57-4, Gold sodium thiomalate 12650-69-0, Mupirocin 12794-10-4D, Benzodiazepine, derivs. 13010-47-4, Lomustine 13292-46-1, Rifampin 13311-84-7, Flutamide 13392-28-4, Rimantadine 13647-35-3, Trilostane 14028-44-5, Amoxapine 14124-50-6 14611-51-9, Selegiline 14769-73-4, Levamisole 14838-15-4, Phenylpropanolamine 14882-18-9, Bismuth subsalicylate 15301-69-6, Flavoxate 15307-86-5, Diclofenac 15663-27-1, Cisplatin 15686-71-2, Cephalexin 15687-27-1, Ibuprofen 15722-48-2, Olsalazine 16051-77-7, Isosorbide mononitrate 16068-46-5, Potassium phosphate 16110-51-3, Cromolyn 16590-41-3, Naltrexone 16679-58-6, Desmopressin 17230-88-5, Danazol 17784-12-2, Sulfacytine 18323-44-9, Clindamycin 18559-94-9, Albuterol 18883-66-4, Streptozocin 19216-56-9, Prazosin 19794-93-5, Trazodone 20537-88-6, Amifostine 20830-75-5, Digoxin 20830-81-3, Daunomycin 21256-18-8, Oxaprozin 21829-25-4, Nifedipine 22204-53-1, Naproxen 22232-71-9, Mazindol 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 23288-49-5, Probucol 25322-68-3, Polyethylene glycol 25451-15-4, Felbamate 25614-03-3, Bromocriptine 25812-30-0, Gemfibrozil 26652-09-5, Ritodrine 26787-78-0, Amoxicillin 26807-65-8, Indapamide 26839-75-8, Timolol 27203-92-5, Tramadol 27262-47-1, Levobupivacaine 27686-84-6, Masoprocol 28395-03-1, Bumetanide 28657-80-9, Cinoxacin 28782-42-5, Difenoxin 28860-95-9, Carbidopa 28911-01-5, Triazolam 28981-97-7, Alprazolam 29094-61-9, Glipizide 29110-47-2, Guanfacine 29122-68-7, Atenolol 30516-87-1, Zidovudine 31441-78-8, Mercaptopurine 31677-93-7, Bupropion hydrochloride 31828-71-4, Mexiletine 31883-05-3, Moricizine 32986-56-4, Tobramycin 33069-62-4, Paclitaxel 33419-42-0, Etoposide 34089-81-1, Sodium ferric gluconate 35189-28-7, Norgestimate 36322-90-4, Piroxicam 36505-84-7, Buspirone 36791-04-5, Ribavirin 38304-91-5, Minoxidil 40180-04-9, Tienilic acid 40580-59-4, Guanadrel 41575-94-4, Carboplatin 41708-72-9, Tocainide 42399-41-7, Diltiazem 42924-53-8, Nabumetone 49562-28-9, Fenofibrate 50679-08-8, Terfenadine 50925-79-6, Colestipol 50972-17-3, Bacampicillin 51022-71-0, Nabilone 51110-01-1, Somatostatin 51333-22-3, Budesonide 51384-51-1, Metoprolol 51481-61-9, Cimetidine 53179-11-6, Loperamide 53230-10-7, Mefloquine 53608-75-6, Pancrelipase 53714-56-0, Leuprolide 53994-73-3, Cefaclor 54024-22-5, Desogestrel 54063-53-5, Propafenone 54143-56-5, Flecainide acetate 54182-58-0, Sucralfate 54350-48-0, Etretinate 54573-75-0, Doxercalciferol 54910-89-3, Fluoxetine 55142-85-3, Ticlopidine 55268-75-2, Cefuroxime 55985-32-5, Nicardipine 56420-45-2, Epirubicin 58001-44-8 58581-89-8, Azelastine 59122-46-2, Misoprostol 59277-89-3, Acyclovir 59729-33-8, Citalopram 59865-13-3, Cyclosporine A 60142-96-3, Gabapentin 60205-81-4, Ipratropium 61489-71-2, Menotropin 61718-82-9, Fluvoxamine maleate 61869-08-7, Paroxetine 62571-86-2, Captopril 63585-09-1, Foscarnet sodium 63590-64-7, Terazosin 64952-97-2, Latamoxef 65141-46-0, Nicorandil 65277-42-1, Ketoconazole 66085-59-4, Nimodipine 66104-22-1, Pergolide 66357-35-5, Ranitidine 66376-36-1, Alendronate 67227-57-0, Fenoldopam mesylate 68475-42-3, Anagrelide 68844-77-9, Astemizole 69049-73-6, Nedocromil 69123-98-4, Fialuridine 69655-05-6, Didanosine 70359-46-5, Brominide tartrate 70989-04-7, S-Mephenytoin 71320-77-9, Moclobemide 72432-03-2, Miglitol 72509-76-3, Felodipine 72956-09-3, Carvedilol 73590-58-6, Omeprazole 74103-06-3, Ketorolac 74191-85-8, Doxazosin 75330-75-5, Lovastatin 75695-93-1, Isradipine 75706-12-6, Leflunomide 75847-73-3, Enalapril 76470-66-1, Loracarbef 76547-98-3, Lisinopril 76568-02-0, Flosequinan 76584-70-8 76824-35-6, Famotidine 76932-56-4, Nafarelin 76963-41-2, Nizatidine 78110-38-0, Aztreonam 78628-80-5, Terbinafine hydrochloride 79516-68-0, Levocabastine

79617-96-2, Sertraline 79794-75-5, Loratadine 79902-63-9, Simvastatin
80125-14-0, Remoxipride 80474-14-2, Fluticasone propionate 81093-37-0,
Pravastatin 81098-60-4, Cisapride 81103-11-9, Clarithromycin
81669-57-0, Anistreplase 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin
82626-48-0, Zolpidem 82834-16-0, Perindopril 83366-66-9, Nefazodone
83799-24-0, Fexofenadine 83881-51-0, Cetirizine 83905-01-5,
Azithromycin 84057-84-1, Lamotrigine 84449-90-1, Raloxifene
84625-61-6, Itraconazole 85441-61-8, Quinapril 85721-33-1,
Ciprofloxacin 86386-73-4, Fluconazole 86541-75-5, Benazepril
87333-19-5, Ramipril 87679-37-6, Trandolapril 88040-23-7, Cefepime
88150-42-9, Amlodipine 89365-50-4, Salmeterol 89778-26-7, Toremifene
90566-53-3, Fluticasone 91714-94-2, Bromfenac
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(methods of determining individual hypersensitivity to a pharmaceutical
agent
from gene expression profile)

IT 92665-29-7, Cefprozil 93390-81-9, Fosphenytoin 93413-69-5, Venlafaxine
93479-97-1, Glimepiride 93957-54-1, Fluvastatin 95058-81-4,
Gemcitabine 95233-18-4, Atovaquone 96036-03-2, Meropenem 97322-87-7,
Troglitazone 97519-39-6, Ceftibuten 97534-21-9, Merbarone
97682-44-5, Irinotecan 98048-97-6, Fosinopril 98319-26-7, Finasteride
100986-85-4, Levofloxacin 102767-28-2, Levetiracetam 103577-45-3,
Lansoprazole 103628-46-2, Sumatriptan 104227-87-4, Famciclovir
104632-26-0, Pramipexole 105102-22-5, Mometasone 105462-24-6
105857-23-6, Alteplase 106133-20-4, Tamsulosin 106266-06-2,
Risperidone 106392-12-5, Poloxamer 188 106650-56-0, Sibutramine
107753-78-6, Zafirlukast 107868-30-4, Exemestane 109889-09-0,
Granisetron 111025-46-8, Pioglitazone 112809-51-5, Letrozole
112965-21-6, Calcipotriene 114798-26-4, Losartan 115103-54-3,
Tiagabine 115956-13-3, Dolasetron mesylate 116644-53-2, Mibefradil
117976-89-3, Rabeprazole 119383-00-5 119914-60-2,
Grepafloxacin 120014-06-4, Donepezil 121679-13-8, Naratriptan
122320-73-4, Rosiglitazone 122647-32-9, Ibutilide fumarate
122852-42-0, Alosetron 123948-87-8, Topotecan 124937-51-5, Tolterodine
126040-58-2, Calcium polycarbophil 127779-20-8, Saquinavir
129311-55-3, Ganirelix acetate 129318-43-0, Alendronate sodium
129618-40-2, Navirapine 130209-82-4, Latanoprost 130929-57-6,
Entacapone 134308-13-7, Tolcapone 134523-00-5, Atorvastatin
137862-53-4, Valsartan 138402-11-6, Irbesartan 143003-46-7,
Alglucerase 144494-65-5, Tirofiban 144701-48-4, Telmisartan
145599-86-6, Cerivastatin 147059-72-1, Trovafloxacin 147245-92-9,
Copolymer 1 150378-17-9, Indinavir 151096-09-2, Moxifloxacin
161814-49-9, Amprenavir 169590-42-5, Celecoxib 171599-83-0, Sildenafil
citrate 172820-23-4, Pexiganan acetate 180288-69-1, Trastuzumab
185243-69-0, Etanercept 188627-80-7, Eptifibatide 339524-26-4,
Amiodorone 339524-30-0, Cyclopegic 339524-35-5, Cytoxin 339524-50-4,
Hyperozia
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(methods of determining individual hypersensitivity to a pharmaceutical
agent
from gene expression profile)

=>